Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox
Clémence Lacroix(Inserm), Olivier Blin(Inserm), Joëlle Micallef(Institut de Neurosciences des Systèmes), Romain Guilhaumou(Hôpital de la Timone)
Cited by 8
Related Papers
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60
Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
|Clinical Pharmacology & Therapeutics|2021|48
Non-targeted screening for novel psychoactive substances among agitated emergency department patients
|Clinical Toxicology|2016|42
Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?
|Revue Neurologique|2023|32